← All trials
NCT06694727
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2025
- Primary completion
- Aug 1, 2028
- Completion date
- Feb 1, 2029
- First posted
- Nov 19, 2024
- Last posted
- Nov 19, 2024
- Enrollment
- 4044
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenOfficial
- University of CopenhagenSponsor investigator
- Pharma NordCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.